Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD

Criteria the registry did not label

• Eligible study subjects must meet all of the following inclusion criteria:
• Informed consent form signed by the study subjects.
• Male or female aged 30 to 80 years on the day of enrolment.
• \> 50% stenosis in one or more major coronary arteries on angiography or computerised tomography (CT) performed within the preceding one year (from enrolment visit).
  • or Myocardial infarction (type I, II) during the preceding year.
  • Eligible study subjects must not meet any of the following exclusion criteria:
• Hospitalisation for acute coronary syndrome, myocardial infarction, stroke, coronary revascularisation or acute heart failure within the preceding one month (30 days). These subjects can be enrolled after a one-month stabilisation period, which begins from the time of the event.
• Subjects with NYHA class III-IV heart failure i.e. marked limitation in activity due to symptoms, comfortable only at rest.
• Uncontrolled arrhythmias such as ventricular tachycardias.
• Subjects undergoing dialysis due to severe renal disease.
• Diseases that severely disable exercising (per investigator's judgement), such as rheumatoid arthritis, neurological or orthopaedic diseases.
• Known aplastic or haemolytic anaemia.
• Concomitant non-coronary disease, such as malignancy that limits life expectancy to less than three years.
• Concurrent participation in another interventional study.
• Subjects not able and/or willing to attend all scheduled visits and comply with all study procedures and use a smartphone application.